Kathryn Dahir Archives
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva
Sep. 28, 2023—A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.
May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.
Aug. 17, 2017—Kathryn Dahir, M.D., associate professor of Medicine in the Division of Diabetes, Endocrinology and Metabolism, recently received the Maher Family Grant from Soft Bones Inc., an organization dedicated to providing information, education and support to those affected by hypophosphatasia (HPP).